News

More than meds: why easier access to ADHD treatment has to be part of a whole-system approach
Increasing access to ADHD diagnosis and medication is a good move. But it shouldn’t be the whole plan to address a condition ...
FDA to revise labeling of ADHD medication to indicate weight loss risk
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
HealthDay on MSN2d
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes.
Clinical Advisor2d
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants.
US FDA to revise label of ADHD medications to add weight loss risk in patients younger than 6
The U.S. Food and Drug Administration said on Monday that it is revising the labeling of all extended-release stimulants to ...
pharmaphorum1d
Managing the UK's ADHD medication supply crisis with accessible technology support - pharmaphorum
ADHD brains are some of the most economically valuable, found in many data scientists, engineers, creatives, entrepreneurs, and more. However, unmanaged ADHD can quickly spill over into trouble.
pharmaphorum3d
ADHD medication scarcity adds to questions on US supply chain
The issues in the supply chain, which ADHD medications are now a part of, have led to greater calls to onshore, or ‘reshore’, manufacturing within the US.